Gary Besser, MD
Obstetrics & Gynecology · Stamford, CTNPI 1992809982
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 408 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Among obstetrics & gynecology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 408 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Astellas Pharma US Inc$1K
- Sumitomo Pharma America, Inc.$813
- Mayne Pharma Commercial LLC$586
- Pfizer$419
- Therapeuticsmd, Inc.$397
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,67099%
- Education$661%
- Gifts$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 58 | $1,208 |
| Astellas Pharma US Inc | 55 | $1,057 |
| Sumitomo Pharma America, Inc. | 39 | $813 |
| Mayne Pharma Commercial LLC | 31 | $586 |
| Pfizer | 26 | $419 |
| Therapeuticsmd, Inc. | 28 | $397 |
| Avion Pharmaceuticals | 26 | $339 |
| Bayer | 16 | $330 |
| Exact Sciences | 13 | $319 |
| Urovant Sciences Inc | 13 | $293 |
| Biogen | 10 | $246 |
| Myovant Sciences Inc. | 14 | $229 |
| Exeltis, USA Inc. | 7 | $220 |
| Coopersurgical, Inc. | 8 | $162 |
| Merck | 9 | $159 |
| Evofem Biosciences, Inc. | 6 | $125 |
| Scynexis, Inc. | 4 | $99 |
| Vertical Pharmaceuticals, LLC | 5 | $83 |
| Millicent US Inc | 4 | $73 |
| AMAG Pharmaceuticals, Inc. | 4 | $66 |
| Aspira Women's Health Inc | 5 | $65 |
| Agile Therapeutics, Inc. | 3 | $60 |
| Duchesnay USA Incorporated | 3 | $57 |
| Organon | 3 | $49 |
| Daiichi Sankyo Inc. | 3 | $47 |
| Medtronic | 1 | $35 |
| Lupin Inc. | 2 | $32 |
| Coloplast | 2 | $32 |
| Baxter Healthcare | 1 | $25 |
| Medicem Inc. | 2 | $23 |
| Sanara Medtech Inc. | 1 | $21 |
| Medline Industries LP | 1 | $20 |
| Innovation Technologies Inc | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $14 |
| Olympus America Inc. | 1 | $13 |
| Ascend Therapeutics US, LLC | 1 | $12 |
| Meditrina | 1 | $4 |
How this compares
$7,747 in reported general payments places this provider in the 95th percentile of 605 obstetrics & gynecology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 53 | $26,521 |
| GemtesaVibegron | 26 | $20,036 |
| Estradiol | 159 | $15,866 |
| ImvexxyEstradiol | 31 | $13,841 |
| YuvafemEstradiol | 49 | $8,166 |
| VagifemEstradiol | 26 | $6,323 |
| BijuvaEstradiol/Progesterone | 11 | $2,525 |
| Estradiol (Once Weekly)Estradiol | 11 | $1,521 |
| Estradiol (Twice Weekly)Estradiol | 11 | $1,470 |
| Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet | 23 | $1,268 |
| Raloxifene Hcl | 47 | $1,247 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 47 | $917 |
| ValacyclovirValacyclovir Hcl | 28 | $828 |
| Oxybutynin Chloride ErOxybutynin Chloride | 13 | $669 |
| Terconazole | 14 | $432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin | $419 | $26,52153 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $813 | $20,03626 claims |
| Therapeuticsmd, Inc.Imvexxy, Bijuva | $397 | $16,36642 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 605 obstetrics & gynecology providers in Connecticut.
Other obstetrics & gynecology in Stamford
- Shieva GhofranyStamford$33K
- Sarp AkselStamford$22K
- Daniel CibulskyStamford$17K
- Patrick CahillStamford$8K
- George HeadingStamford$8K
- Astrid Hoffmann-OlsenStamford$7K
- Robert GennaroStamford$7K
- David WeinsteinStamford$6K
- Stephanie GoldpinStamford$6K
- Artonius PanagiotakisStamford$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.